The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer

被引:29
作者
Clouth, B. [1 ]
Chandrasekharan, S. [1 ]
Inwang, R. [1 ]
Smith, S. [1 ]
Davidson, N. [1 ]
Sauven, P. [1 ]
机构
[1] Broomfield Hosp, Dept Surg, Breast Unit, Chelmsford CM1 7ET, Essex, England
来源
EJSO | 2007年 / 33卷 / 08期
关键词
breast cancer; advanced; neoadjuvant therapy; surgical management;
D O I
10.1016/j.ejso.2006.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Our aim was to investigate the role of minimal surgery in patients with locally advanced breast cancer (LABC) who achieve a complete pathological (pCR) response to primary chemotherapy (PC) and evaluate subsequent local recurrence (LRR), disease free survival (DFS) and overall survival (OS). Methods: Between January 2000 and April 2005, 101 patients with operable LABC (T2, T3, NO or N1, MO) who were not suitable for conservation surgery were treated with PC. Patients were treated with doxorubicin and cyclophosphamide for four cycles (100 patients) then four cycles with paclitaxel (91 patients). Post-PC surgery consisted of multiple core biopsies and axillary clearance for patients with a complete clinical and radiological response. If a pCR was confirmed no further breast surgery was performed. The remaining patients were treated with breast conserving surgery or mastectomy and axillary clearance as appropriate. Adjuvant radiotherapy was given to all patients. Results: Breast conservation was possible in 60% of patients. Overall, 20 patients achieved a pCR of which 16 were confirmed on core biopsies alone. All patients were followed-up for a mean of 33.5 months (95% CI, 30.3-36.7). There were 10 local recurrences, four following mastectomy, four after wide excision and two after core biopsies. There was no difference in DFS (chi square = 0. 18; p = 0.67) or OS (chi square = 0.67; p = 0.41) between patients achieving a pCR and the remainder. Conclusions: The local recurrence rate of these poor prognosis patients is similar to other reported series but higher than in our previously reported series of patients managed according to the same protocol. Our current management therefore now includes pre-treatment marking and Subsequent surgical excision. (C) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:961 / 966
页数:6
相关论文
共 32 条
  • [1] High prognostic significance of residual disease after neoadjuvant chemotherapy:: a retrospective study in 710 patients with operable breast cancer
    Amat, S
    Abrial, C
    Penault-Llorca, F
    Delva, R
    Bougnoux, P
    Leduc, B
    Mouret-Reynier, MA
    Mery-Mignard, D
    Bleuse, JP
    Dauplat, J
    Curé, H
    Chollet, P
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 (03) : 255 - 263
  • [2] [Anonymous], 1958, J AM STAT ASSOC, DOI [DOI 10.1080/01621459.1958.10501452, DOI 10.2307/2281868]
  • [3] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27
    Bear, HD
    Anderson, S
    Brown, A
    Smith, R
    Mamounas, EP
    Fisher, B
    Margolese, R
    Theoret, H
    Soran, A
    Wickerham, DL
    Wolmark, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) : 4165 - 4174
  • [4] Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
    Buzdar, AU
    Singletary, SE
    Theriault, RL
    Booser, DJ
    Valero, V
    Ibrahim, N
    Smith, TL
    Asmar, L
    Frye, D
    Manuel, N
    Kau, SW
    McNeese, M
    Strom, E
    Hunt, K
    Ames, F
    Hortobagyi, GN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3412 - 3417
  • [5] Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy
    Chagpar, AB
    Middleton, LP
    Sahin, AA
    Dempsey, P
    Buzdar, AU
    Mirza, AN
    Ames, FC
    Babiera, GV
    Feig, BW
    Hunt, KK
    Kuerer, HM
    Meric-Bernstam, F
    Ross, MI
    Singletary, SE
    [J]. ANNALS OF SURGERY, 2006, 243 (02) : 257 - 264
  • [6] Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast?
    Chaturvedi, S
    McLaren, C
    Schofield, A
    Ogston, K
    Sarkar, T
    Hutcheon, A
    Miller, I
    Heys, S
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (02) : 151 - 158
  • [7] Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
    Fisher, B
    Brown, A
    Mamounas, E
    Wieand, S
    Robidoux, A
    Margolese, RG
    Cruz, AB
    Fisher, ER
    Wickerham, DL
    Wolmark, N
    DeCillis, A
    Hoehn, JL
    Lees, AW
    Dimitrov, NV
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) : 2483 - 2493
  • [8] Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
    Fisher, B
    Bryant, J
    Wolmark, N
    Mamounas, E
    Brown, A
    Fisher, ER
    Wickerham, DL
    Begovic, M
    DeCillis, A
    Robidoux, A
    Margolese, RG
    Cruz, AB
    Hoehn, JL
    Lees, AW
    Dimitrov, NV
    Bear, HD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2672 - 2685
  • [9] Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
    Guarneri, V
    Broglio, K
    Kau, SW
    Cristofanilli, M
    Buzdar, AU
    Valero, V
    Buchholz, T
    Meric, F
    Middleton, L
    Hortobagyi, GN
    Gonzalez-Angulo, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1037 - 1044
  • [10] Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy
    Hennessy, BT
    Hortobagyi, GN
    Rouzier, R
    Kuerer, H
    Sneige, N
    Buzdar, AU
    Kau, SW
    Fornage, B
    Sahin, A
    Broglio, K
    Singletary, SE
    Valero, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9304 - 9311